Sangamo BioSciences | SGMO - Stock


Sangamo BioSciences reported $0 in Stock for its fiscal quarter ending in March of 2022.





Stock Change Date
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Amgen USD 6.19B 39M Mar/2026
Bayer EUR 12.34B 3M Dec/2025
BioCryst Pharmaceuticals USD 5.98M 587K Mar/2026
Biogen USD 1.95B 219.1M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Cipla INR 61.6B 5.18B Sep/2025
Clal Biotechnology ILS 4.44M 0 Mar/2021
CSL USD 6.47B 327M Jun/2025
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Grifols EUR 3.56B 63.19M Dec/2024
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
J&J USD 14.58B 392M Mar/2026
Karyopharm Therapeutics USD 4.04M 72K Dec/2025
Merck USD 6.48B 179M Mar/2026
Novartis USD 6.29B 17M Mar/2026
Omeros USD 712K 266K Sep/2021
Pfizer USD 10.67B 13M Mar/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Sarepta Therapeutics USD 1B 86.37M Mar/2026
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026